Literature DB >> 11861290

Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors.

Guenther Koehne1, Katherine M Smith, Teresa L Ferguson, Roxanne Y Williams, Glenn Heller, Eric G Pamer, Bo Dupont, Richard J O'Reilly.   

Abstract

Techniques for the quantitation of virus-specific and alloantigen-reactive T cells vary in their measurement of clinically relevant T-cell effector populations, their sensitivity and quantitative accuracy, and the time required to obtain measurable results. We compared frequencies of Epstein-Barr virus (EBV)-specific and major alloantigen-reactive T cells as measured by flow cytometric analysis of responding T cells producing intracellular interferon-gamma (IFN-gamma) and by limiting-dilution analysis (LDA) of cytotoxic T-cell precursors (CTLp) at sequential time points during the generation of EBV-specific T-cell lines. The expansion of EBV-specific T lymphocytes and the depletion of alloreactive T cells in cultures of T cells sensitized with autologous EBV-transformed targets followed similar kinetics when measured by either method. Frequencies of EBV- specific T cells generating intracellular IFN-gamma exceeded by 25- to 90-fold the frequencies of responding CTLp at each stage of expansion, whereas the frequencies of alloreactive T cells generating intracellular IFN-gamma exceeded by 30- to 220-fold those detected by LDA. The assay that quantitated T cells producing IFN-gamma yielded more reproducible and precise results than LDA. Furthermore, frequencies detected by the enumeration of T cells responding to immunodominant EBNA 3a and EBNA 3c peptides by IFN-gamma production or their capacity to bind peptide-HLA tetramers were strikingly similar and represented significant fractions of T cells generating IFN-gamma in response to autologous EBV B lymphoblastoid cell line. Functional analysis of responding viable T cells, fractionated on the basis of their secretion of IFN-gamma, demonstrated that EBV-specific and alloantigen cytotoxic T cells were predominantly or exclusively detected in the CD8(+)IFN-gamma(+) fraction of T cells. Strikingly, the CD4(+)IFN-gamma(+) cell fractions were not cytotoxic against EBV-transformed or allogeneic targets.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861290     DOI: 10.1182/blood.v99.5.1730

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors:  X Wang; I Rivière
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

2.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

3.  Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Authors:  Ekaterina Doubrovina; Taissia Carpenter; Dmitry Pankov; Annamalai Selvakumar; Aisha Hasan; Richard J O'Reilly
Journal:  Blood       Date:  2012-05-23       Impact factor: 22.113

4.  Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen.

Authors:  G Ramadan; B Davies; V P Kurup; C A Keever-Taylor
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

5.  Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen.

Authors:  G Ramadan; B Davies; V P Kurup; C A Keever-Taylor
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

6.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Authors:  Ekaterina Doubrovina; Banu Oflaz-Sozmen; Susan E Prockop; Nancy A Kernan; Sara Abramson; Julie Teruya-Feldstein; Cyrus Hedvat; Joanne F Chou; Glenn Heller; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Diane George; Ann Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Andromachi Scaradavou; Trudy N Small; Ramzi Khalaf; James W Young; Richard J O'Reilly
Journal:  Blood       Date:  2011-12-02       Impact factor: 22.113

7.  WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.

Authors:  Eleanor M Tyler; Achim A Jungbluth; Richard J O'Reilly; Guenther Koehne
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

8.  Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation.

Authors:  Miguel-Angel Perales; Jenna D Goldberg; Jianda Yuan; Guenther Koehne; Lauren Lechner; Esperanza B Papadopoulos; James W Young; Ann A Jakubowski; Bushra Zaidi; Humilidad Gallardo; Cailian Liu; Teresa Rasalan; Jedd D Wolchok; Therese Croughs; Michel Morre; Sean M Devlin; Marcel R M van den Brink
Journal:  Blood       Date:  2012-09-25       Impact factor: 22.113

9.  Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

Authors:  Guenther Koehne; Aisha Hasan; Ekaterina Doubrovina; Susan Prockop; Eleanor Tyler; Gloria Wasilewski; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-29       Impact factor: 5.742

10.  Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.

Authors:  Eleanor M Tyler; Achim A Jungbluth; Sacha Gnjatic; Richard J O'Reilly; Guenther Koehne
Journal:  Cancer Immunol Res       Date:  2014-03-03       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.